High signal intensity on T1-weighted magnetic resonance images (MRI) and low diffusion coefficient values can accurately differentiate uterine leiomyosarcoma from benign leiomyoma, according to a meta-analysis in the Journal of the Belgium Society of Radiology.
However, although leiomyosarcoma had a higher pooled sensitivity for T2-weighted increased signal intensity compared to benign leiomyoma, the difference was not statistical significance.1
“Despite current advances in imaging, there remains a lack of consensus regarding which MRI features are useful for differentiating leiomyosarcoma from benign leiomyoma,” wrote the authors.
The purpose of the analysis was to compare the diagnostic performance of increased signal intensity on T1- and T2-weighted magnetic resonance images and apparent diffusion coefficient (ADC) values in differentiating the two types of tumors.
Diffusion-weighted imaging, which is based on the diffusion motion of water molecules, is widely employed to distinguish between malignant and benign tumors by measuring the ADC value. In essence, a low ADC value correlates with malignant lesions because their higher cellularity and total nuclear area restrict water diffusion.
The analysis consisted of eight studies with 795 patients by searching PubMed/Medline, the Cochrane Library, Embase and Web of Science for all available literature published in English through December 2019.
For leiomyosarcoma (60 patients), increased signal on T1-weighted imaging had a pooled sensitivity of 56.8% (95% confidence interval [CI]: 20% to 87.4%), which was significantly higher than 7.6% (95% CI: 2.2% to 22.7%) for benign leiomyoma (1,272 patients) (P = 0.0094).
However, increased signal analysis on T2-weighted imaging had pooled sensitivities of 93.2% and 93.2% (95% CI: 45.7% to 99.6% and 42.9% to 99.6%) for leiomyosarcoma (90 patients), which were not significantly different from the 54.5% and 53.9% (95% CI: 33.6% to 74% and 32% to 74%) for benign leiomyoma (215 patients) (P = 0.102 and 0.112).
Conversely, for ADC, leiomyosarcoma (43 patients) had a weighted mean and standard deviation of 0.896 ± 0.19 10-3 mm2/s and 0.929 ± 0.182 10-3 mm2/s, respectively, which were significantly lower than 1.258 ± 0.303 10-3 mm2/s and 1.304 ± 0.303 10-3 mm2/s, respectively, for benign leiomyoma (159 patients) (P = < 0.0001, < 0.0001).
The findings of the analysis for ADC values agree with most previous studies, according to the authors, which have also concluded that the weighted mean and standard deviation for leiomyosarcoma are significantly lower than for benign leiomyoma.
Overall, “The results of our meta-analysis indicate that increased signal intensity on T1 weighted image and low ADC values can provide accurate differentiation,” wrote the authors.
Nonetheless, three limitations of the analysis are the small number of included studies; combining data from studies without standardized protocols or techniques that may have resulted in bias and yielded outcomes that are challenging to interpret and translate to clinical practice; and sparse data on lesion size, benign leiomyoma type, uterine sarcoma type, interreader variability in MRI reporting and temporal parameters that can impact the diagnostic performance of MRI.
The authors recommend prospective studies with larger cohorts to advance the consensus on the significant MRI features of leiomyosarcoma and benign leiomyoma.
__
Reference
Laparoscopic RFA linked to enhanced pregnancy outcomes in uterine fibroid patients
May 18th 2024A recent study presented at the 2024 ACOG Clinical and Scientific Meeting reveals that laparoscopic radiofrequency ablation significantly improves pregnancy outcomes for women with uterine leiomyomas.
Read More
Pap Talk S4E4: RFA and uterine fibroids with Dr. Jessica Shepherd
March 30th 2022In this episode of Pap Talk, Jessica Shepherd, MD, MBA, FACOG, deep dives into the benefits of utilizing radio frequency ablation (RFA) for treatment of uterine fibroids, available RFA devices, and disparities in the condition.
Listen
Study finds antihypertensive treatment reduces uterine fibroids risk
April 23rd 2024A recent study revealed that patients with untreated or new-onset hypertension face elevated chances of uterine fibroid diagnosis, underscoring the potential of antihypertensive therapy in mitigating this risk among midlife individuals.
Read More
Physician-patient collaboration for uterine fibroid treatment options
May 12th 2021Contemporary OB/GYN®’s senior editor Angie DeRosa sat down with Ayman Al-Hendy, MD, and Sateria Venable of The Fibroid Foundation, to discuss the role of patient-physician collaboration in uterine fibroid treatment and management options.
Listen
Maternal history linked to uterine fibroid risk in Black women
April 11th 2024Delve into the findings of a recent study revealing the heightened risk of developing uterine fibroids among Black women with a maternal history of the condition, shedding light on crucial implications for patient care and advocacy.
Read More
Study finds relugolix-CT Improves HMB in Black women
February 19th 2024Recent research highlights the efficacy and safety of relugolix combination therapy in managing uterine fibroid-associated heavy menstrual bleeding specifically among Black women, demonstrating outcomes comparable to the broader population.
Read More